Although it has taken almost a decade, significant new advances have been made in this area, including the clinical development of modern hormonal therapies, such as abiraterone and enzalutamide ...
The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...
enzalutamide or abiraterone? We would need to do randomized trials of sequential treatments to answer these questions. When the data of ECOG 3809 (randomized trial of chemotherapy- docetaxel for 6 ...
An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...
Medpage Today on MSN8d
Radiographic PFS in Metastatic CRPC More Than Doubles With Novel CombinationRadiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) more than doubled ...
With the development of the newer agents, abiraterone acetate and enzalutamide, efforts have been made to better define the basis for response and resistance. This work can be carried out in cell ...
Overall, 28% received combination therapy with ARPI (18% abiraterone; 10% apalutamide, darolutamide, or enzalutamide), 9% with DOC, and 2.5% with ARPI plus DOC. From 2017 to 2023, combined hormonal ...
The drug was more effective than the modern hormone treatments abiraterone and enzalutamide at slowing down the growth and spread of prostate cancer in patients with advanced disease, the results ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback